NASDAQ:LMNX - Luminex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $29.59 -0.20 (-0.67 %) (As of 09/20/2018 12:01 PM ET)Previous Close$29.79Today's Range$29.49 - $29.9152-Week Range$18.62 - $35.37Volume5,629 shsAverage Volume244,408 shsMarket Capitalization$1.35 billionP/E Ratio32.52Dividend Yield0.80%Beta0.24 Company ProfileDiscussionAnalyst RatingsChartDividend HistoryEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group B strep assays, ARIES group A strep assays, ARIES bordetella assays, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas. Receive LMNX News and Ratings via Email Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical SymbolNASDAQ:LMNX CUSIP55027E10 Webwww.luminexcorp.com Phone512-219-8020 Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio5.33 Price-To-Earnings Trailing P/E Ratio32.52 Forward P/E Ratio51.02 P/E Growth3.48 Sales & Book Value Annual Sales$306.57 million Price / Sales4.31 Cash Flow$1.3827 per share Price / Cash21.40 Book Value$9.94 per share Price / Book2.98 Profitability EPS (Most Recent Fiscal Year)$0.91 Net Income$29.42 million Net Margins10.57% Return on Equity7.44% Return on Assets6.76% Miscellaneous Employees922 Outstanding Shares44,610,000Market Cap$1.35 billion Luminex (NASDAQ:LMNX) Frequently Asked Questions What is Luminex's stock symbol? Luminex trades on the NASDAQ under the ticker symbol "LMNX." How often does Luminex pay dividends? What is the dividend yield for Luminex? Luminex declared a quarterly dividend on Wednesday, September 12th. Investors of record on Friday, September 21st will be paid a dividend of $0.06 per share on Friday, October 12th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date is Thursday, September 20th. View Luminex's Dividend History. How were Luminex's earnings last quarter? Luminex Co. (NASDAQ:LMNX) posted its quarterly earnings results on Monday, August, 6th. The medical instruments supplier reported $0.15 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.19 by $0.04. The medical instruments supplier had revenue of $79.60 million for the quarter, compared to the consensus estimate of $79.66 million. Luminex had a return on equity of 7.44% and a net margin of 10.57%. Luminex's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.26 EPS. View Luminex's Earnings History. When is Luminex's next earnings date? Luminex is scheduled to release their next quarterly earnings announcement on Monday, October, 29th 2018. View Earnings Estimates for Luminex. What price target have analysts set for LMNX? 4 equities research analysts have issued 1-year target prices for Luminex's stock. Their forecasts range from $22.00 to $34.00. On average, they anticipate Luminex's stock price to reach $27.25 in the next year. This suggests that the stock has a possible downside of 7.8%. View Analyst Price Targets for Luminex. What is the consensus analysts' recommendation for Luminex? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex. Who are some of Luminex's key competitors? Some companies that are related to Luminex include Penumbra (PEN), Globus Medical (GMED), Novocure (NVCR), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Glaukos (GKOS), Nevro (NVRO), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Cryolife (CRY), Tactile Systems Technology (TCMD) and AtriCure (ATRC). Who are Luminex's key executives? Luminex's management team includes the folowing people: Mr. Nachum Shamir, CEO, Pres & Director (Age 64)Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 56)Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 50)Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 48)Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 56) Has Luminex been receiving favorable news coverage? Headlines about LMNX stock have been trending somewhat positive recently, according to Accern Sentiment. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Luminex earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news articles about the medical instruments supplier an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Luminex. Who are Luminex's major shareholders? Luminex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.83%), Renaissance Technologies LLC (4.47%), Dimensional Fund Advisors LP (4.39%), RGM Capital LLC (3.88%), Acadian Asset Management LLC (3.55%) and Northern Trust Corp (2.17%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex. Which major investors are selling Luminex stock? LMNX stock was sold by a variety of institutional investors in the last quarter, including RGM Capital LLC, Renaissance Technologies LLC, Alambic Investment Management L.P., Russell Investments Group Ltd., DAFNA Capital Management LLC, Investment Management of Virginia LLC, Point72 Asset Management L.P. and Fisher Asset Management LLC. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II and Todd C Bennett. View Insider Buying and Selling for Luminex. Which major investors are buying Luminex stock? LMNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., WINTON GROUP Ltd, Acadian Asset Management LLC, Federated Investors Inc. PA, Spark Investment Management LLC, Schwab Charles Investment Management Inc., TD Asset Management Inc. and Citadel Advisors LLC. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex. How do I buy shares of Luminex? Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Luminex's stock price today? One share of LMNX stock can currently be purchased for approximately $29.57. How big of a company is Luminex? Luminex has a market capitalization of $1.35 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe. How can I contact Luminex? Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected] MarketBeat Community Rating for Luminex (NASDAQ LMNX)Community Ranking: 1.9 out of 5 ()Outperform Votes: 173 (Vote Outperform)Underperform Votes: 289 (Vote Underperform)Total Votes: 462MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: How Do You Make Money With Penny Stocks?